One to One, One to Few, One to Many: Choosing the Right ABM Model for Your Business

Account-Based Marketing is not a single approach. It exists on a spectrum from highly bespoke, resource-intensive engagement with a handful of elite accounts, to scalable programmatic campaigns reaching hundreds of companies simultaneously. Especially in B2B life sciences marketing, understanding where your organization should sit on that spectrum, and for which accounts, is one of the most consequential decisions in building an effective ABM program.

The three primary ABM models — One-to-One, One-to-Few, and One-to-Many — each serve a distinct purpose, require a different level of resource investment, and produce different types of commercial outcomes. Most mature ABM programs deploy all three simultaneously, applying each to the appropriate tier of the account list. Getting that allocation right is what separates programs that generate strong ROI from those that spread resources too thin or concentrate them in the wrong places.

This post explains each model in detail, how to determine the right fit for your accounts, and how to architect a tiered program that applies the right approach to the right accounts.

Comparing ABM Deployment Frameworks

One-to-One ABM: Targeting Key Strategic Accounts

One-to-One ABM treats each target account as its own individual market. Every element of the commercial engagement including the content, the advertising, the messaging and value propositions, the landing pages, and the BD outreach is customized specifically for that account. This level of customization is resource-intensive both from the time required and budget needed to execute effectively.

Given this, a One-to-One approach is generally appropriate only for a small number of accounts at the very top of your target list. These are organizations where a secured contract would represent a material impact on annual revenue, and where the complexity and duration of the sales process justify sustained, resource-intensive engagement. In practice, most organizations have only a handful of accounts in this category, and rarely more than 5% of their total ICP account list.

What One-to-One ABM looks like in practice

In One-to-One ABM, the marketing team develops assets and digital destinations to a single target company. Rather than a generic capabilities landing page, the account receives a purpose-built digital destination that references things like their known pipeline, their therapeutic focus, or scientific focus, and then explains exactly how your solution is positioned to help with the challenges they are navigating right now.

Content developed for One-to-One ABM might include a custom technical brief mapping your capabilities directly to the account's publicly announced development programs, a bespoke ROI analysis built around their organizational profile, or a thought leadership piece that addresses a specific regulatory or operational challenge the account is known to be facing.

BD and sales engagement runs in parallel: the commercial team maps the buying committee at the account, identifies the internal champion and key decision-makers, and executes highly personalized outreach informed by the specific content each individual has engaged with. Executive-level peer engagement, like a meeting between your Chief Scientific Officer and their Head of Clinical Development, is often part of the One-to-One playbook for the most strategic accounts.

The deal threshold that typically justifies One-to-One ABM varies by organization and industry, but in B2B life sciences, it’s generally reserved for accounts with expected contract values in the millions of dollars over a multi-year engagement. Below that threshold, the math rarely works.

One-to-Few ABM: Focusing on Revenue-Generating Segments at Scale

One-to-Few ABM targets ICP segments or groups of accounts that share meaningful characteristics. Examples include the same therapeutic area, the same development stage, the same outsourcing model, or the same organizational profile. Rather than customizing for each individual account, the commercial team creates messaging and content calibrated to the shared needs of the segment. The result is a level of relevance and personalization that feels genuinely tailored to each account in the group, without the resource intensity of account-by-account customization.

This is the most versatile of the three ABM models, and for many B2B life science companies it is the most valuable entry point when building an ABM program for the first time. The typical segment size ranges from ten to one hundred accounts, and the minimum deal threshold that makes the investment worthwhile is generally in the range of $50,000 to $100,000 although this varies significantly depending on the nature of the offering and the length of the sales cycle.

Building effective segments

The quality of a One-to-Few campaign depends heavily on how the segment is constructed. The goal is to find a grouping of accounts with a shared challenge or shared context specific enough that you can speak directly to it in your messaging, and credibly claim genuine expertise in addressing it.

In life sciences, effective ways to segment your ICP to create a target group include criteria such as: companies developing assets in a specific modality and development stage (e.g., cell therapy programs in Phase 1/2 transition), companies with a specific funding profile and outsourcing history (e.g., Series B/C biotechs with a CRO-heavy operating model), or companies within a therapeutic area facing a common regulatory inflection point.

The more specific the shared characteristic, the more resonant the messaging can be. A campaign targeting "biotechs with oncology assets preparing for first-in-human trials" can deploy content that addresses the exact operational and scientific challenges that cohort is navigating. That level of specificity helps your messages and offering stand out to companies with those needs.

What One-to-Few ABM looks like in practice

A One-to-Few campaign typically includes a segment-specific landing page along with content assets (white papers, webinars, case studies) directly addressing the segment's shared challenges. LinkedIn ad campaigns target the relevant personas at the accounts in the targeted segment, ideally using messaging aligned to each persona's specific role and concerns. SDR outreach sequences are created that build off the outreach and engagement content, again tailored to the relevant personas.

The goal is to find accounts with multiple individuals that are engaging with the content in the campaign, and then elevate those accounts for increased marketing attention (potentially shifting from using top of funnel to using middle of the funnel content) while notifying sales of the account engagement so that the sales team can reach out via an SDR sequence or more personalized outreach.

One-to-Many ABM: Broad Brand-Building through Programmatic Content

One-to-Many ABM targets the broadest segment of a target account universe: the accounts that meet your ICP baseline criteria but do not yet demonstrate the revenue potential or buying signals to warrant the investment of One-to-Few or One-to-One treatment. This group typically represents the majority of the total account list, often 65 to 80% of the broad ICP.

The purpose of One-to-Many ABM is twofold: build brand familiarity and category authority across a wide pool of potential future customers, and monitor that pool continuously for the engagement signals that indicate an account may be moving into an active buying cycle.

What One-to-Many ABM looks like in practice

One-to-Many ABM relies on programmatic advertising and content syndication at scale. Display ads serve consistent, high-level messaging to employees at all accounts on the list. This messaging is typically not personalized by account or segment, but is still relevant to the broader audience defined by the ICP. In One-to-Many ABM, we are also tracking and monitoring any accounts that show higher engagement with content, and also monitoring first part intent data (engagement with any marketing emails sent, visits to your company web site, attendance at webinars, etc.)

The signals at the account level from engaging with the campaign, combined with tracked web site visit data and marketing content engagement, is the most important output in One-to-Many ABM. When an account in the broad target pool begins showing elevated engagement — multiple employees visiting the website, specific content being downloaded, ad interaction rates rising — that account becomes a candidate for elevation to One-to-Few or, in some cases, direct sales and BD outreach.

In this way, One-to-Many ABM functions as an intelligence-gathering layer as much as a marketing one. It keeps your brand visible across the full ICP, while surfacing the accounts that are beginning to move into an active buying cycle before your competitors have identified them.

Comprehensive ABM: Running All Three Simultaneously

The most effective ABM programs do not choose one of these models. They run all three concurrently, applying each to different segments of the broad ICP target list and moving accounts between tiers as engagement signals and market conditions evolve.

In a well-architected blended program, a few key strategic accounts receive full One-to-One treatment. The next tier of accounts are organized into One-to-Few segments based on shared characteristics, each segment put into a specific ABM campaign. The remainder of the full ICP account universe receives One-to-Many programmatic engagement. All campaigns are monitored for engagement data, intent data, and life science-specific intent signals like new funding rounds or new trials. Account can be elevated from a One-to-Many campaign into a One-to-Few campaign based on these signals, or moved into direct BD outreach. This continuous monitoring and updating of account targeting lists is a key feature of a mature ABM program.

Determining the right blend for your organization

The right distribution across the three models depends on several factors: the nature of your commercial offering, the size of your addressable market, your average deal value, and the maturity of your commercial infrastructure.

Organizations offering highly specialized services with large deal values and a narrow addressable market (a specialized CRO serving only late-phase oncology programs, for example) should weight their investment heavily toward One-to-One and One-to-Few. The market is too small for broad One-to-Many campaigns alone to generate meaningful ROI, and the revenue potential of each account in the ICP justifies deep investment.

Organizations offering services with broader applicability and moderate deal values such as standardized laboratory testing, research tools, or software platforms will find One-to-Many and One-to-Few doing more of the heavy lifting, with One-to-One reserved for only the largest and most strategically important accounts.

There is no universal ratio. What matters is that the investment at each tier is proportionate to the expected return, and that intelligence signals are constantly used to determine the best action for accounts and to add new accounts to targeting as needed.

The Organizing Logic of Tiered ABM

The underlying principle connecting all three models is straightforward: in any commercial program, resources are finite, and deploying them proportionally to expected return is the discipline that drives ROI.

One-to-One, One-to-Few, and One-to-Many are not just tactical variations. They are an expression of that principle and a framework for ensuring that the accounts with the greatest potential receive the investment their potential warrants, while the broader account universe remains engaged and monitored. Getting that balance right is the architecture of an ABM program that grows more effective, and more efficient, over time.